hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06319846 id: ZLRK202312 briefTitle: Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4） overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-06 date: 2026-06 date: 2024-03-20 date: 2024-03-20 name: Beijing Tiantan Hospital class: OTHER briefSummary: The CHANCE-4 study is a multicenter, double-blind, double-simulation, randomized controlled study. In patients at high-risk for mild ischemic stroke or transient ischemic attack with symptomatic intracranial artery stenosis within 24 hours of onset, we will examine whether treatment with tirofiban for 48 hours reduce the risk of ischemic stroke recurrence within 90 days compared with placebo. conditions: Ischemic Stroke, Acute conditions: TIA conditions: Symptomatic Intracranial Artery Stenosis studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 4674 type: ESTIMATED name: Tirofiban name: Tirofiban placebo measure: New ischemic stroke measure: BARC type 3 or type 5 bleeding measure: New ischemic stroke measure: Any new vascular events measure: Proportion of patients with disabling stroke measure: Occurrence and severity of stroke or transient ischemic attack measure: Proportion of patients with aggravated neurological impairment measure: BARC type 3 or type 5 bleeding measure: All bleeding events measure: Death measure: Adverse events or serious adverse events measure: BARC type 2 or type 3 or 5 bleeding sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The 2nd Affiliated Hospital of Harbin Medical University city: Harbin state: Heilongjiang zip: 150086 country: China name: Lihua Wang role: CONTACT phone: 13100881600 email: wanglh211@163.com lat: 45.75 lon: 126.65 facility: People's Hospital of Qihe County city: Dezhou state: Shandong zip: 251199 country: China name: Haitao Li role: CONTACT phone: 13869215737 email: userfiled@126.com lat: 37.45127 lon: 116.31046 facility: Liaocheng People's Hospital（Liaocheng Brain Hospital） city: Liaocheng state: Shandong zip: 252001 country: China name: Xiafeng Yang role: CONTACT phone: 13326356005 email: Cranialnerves@163.com lat: 36.45596 lon: 115.97766 facility: Third People's Hospital of Liaocheng city: Liaocheng state: Shandong zip: 252004 country: China name: Liguo Chang role: CONTACT phone: 17763559299 email: chliguo@163.com lat: 36.45596 lon: 115.97766 facility: Yantai Penglai traditional Chinese medicine hospital city: Yantai state: Shandong zip: 265699 country: China lat: 37.47649 lon: 121.44081 hasResults: False
nctId: NCT06319833 id: 348CER23 briefTitle: Effects of Brain Breaks on Educational Achievement in School Settings: The Break4Brain Project overallStatus: ACTIVE_NOT_RECRUITING date: 2024-01-08 date: 2024-04 date: 2024-07 date: 2024-03-20 date: 2024-03-20 name: University of the Balearic Islands class: OTHER name: Ministry of Science and Innovation name: European Regional Development Fund name: Spanish State Research Agency briefSummary: A total of 600 children between 10 and 12 years of age will be randomized among two experimental conditions: physical activity interacting with a video (n = 300), and sedentary activity (n = 300). The experimental condition will take place in the school settings during the school day through a between-subject design with a total of two measurements, pre, and post-test. Using the latest advances, the transient effects of the experimental conditions on cognitive and academic performance will be measured. The experimental condition was crafted through a qualitative design involving semi-structured interviews with teachers (n = 41) and members of the management team (n = 16), along with questionnaires administered to students (n = 600). To enhance and ensure its sustainability, the same process will be replicated after the intervention. Interviews and questionnaires were meticulously crafted by the RE-AIM framework, and subsequently validated through a rigorous process involving an expert panel (n = 30) utilizing the Delphi methodology. This project has the potential to substantially contribute to the field of acute physical activity and could have a meaningful transference on the educational system. This method might be prescribed as an effective teaching strategy. conditions: Physical Activity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 600 type: ESTIMATED name: Physical activity interacting with a video measure: Academic achievement measure: Inhibition-attention and cognitive flexibility measure: Working memory measure: Selective attention measure: Design of active breaks: semi-structured questionnaires measure: Design of active breaks: semi-structured interviews measure: Physical activity patterns measure: Self-report physical activity patterns measure: Self-report sedentary patterns measure: Self-report physical fitness measure: Socioeconomic level measure: Student's behavior measure: Body composition measure: Creativity sex: ALL minimumAge: 10 Years maximumAge: 12 Years stdAges: CHILD facility: University of the Balearic Islands city: Palma state: Balearic Islands zip: 07122 country: Spain lat: 39.56939 lon: 2.65024 hasResults: False
nctId: NCT06319820 id: 42756493BLC3004 id: 2023-507684-19 type: EUDRACT_NUMBER briefTitle: A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer acronym: MoonRISe-1 overallStatus: RECRUITING date: 2024-04-18 date: 2028-06-28 date: 2028-06-28 date: 2024-03-20 date: 2024-04-25 name: Janssen Research & Development, LLC class: INDUSTRY briefSummary: The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC. conditions: Non-Muscle Invasive Bladder Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 540 type: ESTIMATED name: TAR-210 name: Gemcitabine name: MMC measure: Disease Free Survival (DFS) measure: Time to next Treatment (TTNT) measure: High Grade Recurrence-free Survival (HG RFS) measure: Progression Free Survival (PFS) measure: Rate of Diagnostic and Therapeutic Invasive Urological Interventions after Study Treatment measure: Number of Participants With Adverse Events (Including Physical Examination, Vital Signs and Laboratory Abnormalities) measure: Overall Survival (OS) measure: European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire Core-30 items (EORTC-QLQ-C30) Scores measure: European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire for Non muscle Invasive Bladder Cancer (EORTC-QLQ-NMIBC24) Scores measure: Percentage of Participants With Significant Change From Baseline in EORTC-QLQ-C30 Scores measure: Percentage of Participants With Significant Change From Baseline in EORTC-QLQ-NMIBC24 Scores sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Arkansas Urology status: RECRUITING city: Little Rock state: Arkansas zip: 72211 country: United States lat: 34.74648 lon: -92.28959 facility: Genesis Research LLC status: RECRUITING city: Los Alamitos state: California zip: 90720 country: United States lat: 33.80307 lon: -118.07256 facility: Genesis Research LLC status: RECRUITING city: Sherman Oaks state: California zip: 91411 country: United States lat: 34.15112 lon: -118.44925 facility: MidLantic Urology status: RECRUITING city: Bala-Cynwyd state: Pennsylvania zip: 19004 country: United States lat: 40.00761 lon: -75.23407 facility: Urology Associates status: RECRUITING city: Nashville state: Tennessee zip: 37209 country: United States lat: 36.16589 lon: -86.78444 facility: Urology Austin status: RECRUITING city: Austin state: Texas zip: 78745 country: United States lat: 30.26715 lon: -97.74306 facility: Hadassah University Hospita - Ein Kerem status: RECRUITING city: Jerusalem zip: 9112001 country: Israel lat: 31.76904 lon: 35.21633 hasResults: False
nctId: NCT06319807 id: IRB00110194 briefTitle: GrowWell - Responsive Bottle Feeding overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-12 date: 2025-02 date: 2024-03-20 date: 2024-03-20 name: Wake Forest University Health Sciences class: OTHER briefSummary: The overall goal of this research is use digital health to augment the clinical encounter with Women, Infants, and Children (WIC) clinicians and prevent rapid infant weight gain among children living in low-income households. Intervening on weight gain during infancy offers an opportunity to influence lifelong obesity risk. Using personalized motivational messages and targeted skills-training resources, the intervention will support parents and caregivers in adopting responsive feeding strategies. Knowledge gained from this project will be used to develop a future, larger grant submission focused on developing healthy feeding and eating habits among mother-infant dyads. conditions: Bottle Feeding studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: SINGLE whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: Digital Health Intervention name: Safety Control measure: Engagement - average text message completion rate measure: Satisfaction Scores - Acceptability measure: Satisfaction Scores - Frequency measure: Satisfaction Scores - Timing sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Wake Forest University Health Sciences city: Winston-Salem state: North Carolina zip: 27157 country: United States name: Melissa C Kay, PhD role: CONTACT phone: 781-249-3062 email: mekay@wakehealth.edu lat: 36.09986 lon: -80.24422 hasResults: False
nctId: NCT06319794 id: TQR-BTOP-101 briefTitle: Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-12 date: 2024-12 date: 2024-03-20 date: 2024-03-22 name: TORQUR class: INDUSTRY briefSummary: The aim of the study is to evaluate efficacy and safety of bimiralisib gel treatment for treatment of actinic keratosis (AK) on the face and/or scalp and/or back of hands conditions: Actinic Keratosis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Bimiralisib name: Bimiralisib measure: Change from baseline in AK lesions as measured by achieving an Investigator Global Assessment (IGA) score of 0 or 1 measure: Proportion of participants with partial or complete clearance of AK lesions at the End of Treatment Visit (Week 2 or 4 depending on treatment arms) measure: Incidence of Treatment-Emergent Adverse Events measure: Incidence of local skin reactions sex: ALL minimumAge: 50 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Basel / Department of Dermatology city: Basel country: Switzerland name: Alexander Navarini role: CONTACT lat: 47.55839 lon: 7.57327 facility: CHUV centre hospitalier universitaire vaudois / Department of Dermatology and Venereology city: Lausanne country: Switzerland name: Olivier Gaide role: CONTACT lat: 46.516 lon: 6.63282 hasResults: False
nctId: NCT06319781 id: H-23038433 briefTitle: A Pilot Cohort Study of Risk Factors and Novel Methods of Skin Lesion Assessments in Adults With Atopic Dermatitis, Alopecia Areata, Psoriasis or Vitiligo acronym: Derma-001 overallStatus: RECRUITING date: 2023-12-15 date: 2025-05 date: 2025-05 date: 2024-03-20 date: 2024-03-20 name: Blueskin AS class: INDUSTRY briefSummary: The objective of the study is to explore various clinical and biochemical parameters and their potential associations with disease severity, activity, and prognosis in atopic dermatitis, psoriasis, alopecia areata, and vitiligo. Further, the study aims at validating remote assessments of skin lesions, using smartphone-acquired photos. The study will also assess the feasibility and compliance with weekly remote-assessments and patient-reported data collection over the full study period of one year. The study will observe patients through a period of one year and will provide detailed information concerning the type and dose of medication used, as well as data to evaluate the disease activity with high resolution during this period. The study will involve collection of serum samples for exploratory biomarkers, and punch biopsies. A total of approximately 370 patients, divided into the four disease areas of atopic dermatitis, alopecia areata, psoriasis, and vitiligo, will be enrolled in the study. Using a combination of self-reported and on-site assessments and procedures, the intent is to observe the natural history of patients with select dermatological conditions, investigate tissue characteristics associated with disease activity and symptoms, and evaluate the validity of remote assessment of lesions, and feasibility of weekly self-acquired smart-phone images of skin lesions for remote assessment. conditions: Alopecia Areata conditions: Vitiligo conditions: Atopic Dermatitis conditions: Psoriasis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 370 type: ESTIMATED name: Observational measure: Severity of the disease. measure: Clinical characteristics and disease activity. measure: Tissue profiling and disease activity. measure: Disease activity and biomarkers. measure: Quality of life. measure: Compliance of remote tasks. measure: Quality of smartphone collected photos. measure: Level of agreement between the in-person and remote scoring sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sanos Clinic, Gandrup status: RECRUITING city: Gandrup zip: 9362 country: Denmark name: Cecilie Rovsing, MD role: CONTACT phone: +45 7370 8220 email: info.nordjylland@sanosclinic.com lat: 56.74249 lon: 9.82298 facility: Sanos Clinic, Herlev status: RECRUITING city: Herlev zip: 2730 country: Denmark name: Zarqa Ali, PhD role: CONTACT phone: +45 7370 8200 email: info@sanosclinic.com lat: 55.72366 lon: 12.43998 facility: Sanos Clinic, Vejle status: RECRUITING city: Vejle zip: 7100 country: Denmark name: Randi Kviesgaard Bechmann, MD role: CONTACT phone: +45 7370 8210 email: info.syddanmark@sanosclinic.com lat: 55.70927 lon: 9.5357 hasResults: False
nctId: NCT06319768 id: soh-med-24-01-04ms briefTitle: Efficacy of Intralesional Injection of Pentoxifylline, Platelet-Rich Plasma, and Combined Pentoxifylline With Platelet-Rich Plasma in Patients With Atrophic Acne Scars overallStatus: RECRUITING date: 2024-01-01 date: 2024-06-15 date: 2024-06-15 date: 2024-03-20 date: 2024-03-20 name: Sohag University class: OTHER briefSummary: Platelet-rich plasma (PRP) is an Acne vulgaris is a common chronic inflammatory skin disorder. It is the eighth most prevalent disease worldwide with a prevalence of 9.4%. Acne scar is one of the most persistent complications of acne, causes marked psychological stress to the patient . The process of acne scar formation can be broadly divided into two stages: increased tissue formation and loss or damage of tissue, corresponding to keloid or hypertrophic scar and atrophic scar, respectively.
The ultimate severity of acne scars is correlated with acne grade and the delay in treatment of active disease. The atrophic scars include three subtypes: icepick or V-shaped, rolling or M-shaped, and boxcar or U-shaped scars. Among atrophic scars, the ice pick type represents 60%-70%; the boxcar type represents 20%-30%; and the rolling type represents 15%-25% (Salameh and Shumaker, 2022). According to the qualitative scarring grading system, a macular acne scar type also exists, which clinically shows erythematous, hyperpigmented, or hypopigmented flat marks.
autologous blood product containing high concentrations of platelets in a small volume of plasma. PRP has been utilized in the treatment of orthopedic, musculoskeletal, and maxillofacial conditions for many years, it has only recently gained popularity in dermatology. PRP contains various growth factors, including platelet-derived growth factor (PDGF), transforming growth factor (TFG), vascular endothelial growth factor (VEGF), and insulin-like growth factor (IGF). These growth factors stimulate tissue remodeling and are associated with enhanced healing through the attraction of macrophages, upregulation of collagen synthesis, and promotion of tissue regeneration. Moreover, platelet-derived growth factor (PDGF) was shown to promote wound healing, angiogenesis, and tissue remodeling. conditions: Atrophic Acne Scar studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 75 type: ESTIMATED name: Pentoxifylline name: platelet rich plasma name: combined pentoxifylline and platelet rich plasma measure: goodman and baron qualitative grading system of postacne scarring sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sohag university Hospital status: RECRUITING city: Sohag country: Egypt name: Magdy M Amin, professor role: CONTACT lat: 26.55695 lon: 31.69478 hasResults: False
nctId: NCT06319755 id: X23-0230 briefTitle: Characteristics of Intestinal Microbiome Following Pancreatic Surgery overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-08 date: 2025-02 date: 2024-03-20 date: 2024-03-20 name: Royal Prince Alfred Hospital, Sydney, Australia class: OTHER briefSummary: The goal of this observational study is to learn about intestinal microbiome structure and function in individuals who have undergone a pancreatoduodenectomy and compare to healthy matched controls.
* Stool sample test using Microba Insight TradeMark (a small swab is taken from soiled toilet paper, sealed in a room-temperature storage capsule and mailed to the testing laboratory) conditions: Pancreatic Cancer conditions: Microbiota conditions: Pancreatoduodenectomy studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 20 type: ESTIMATED measure: Comparison of microbiota profile between post-surgical participants and healthy controls. measure: Compliance with 3-day food dairies measure: Pre-paid return rates measure: Ease of matching measure: Shannon diversity index measure: Gastrointestinal symptoms measure: Protein:fibre ratio of diet sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06319742 id: NSISTRCR_2201 briefTitle: Extracellular Vesicle Surface Markers In Acute Cerebrovascular Syndromes. acronym: ElViS-ACS overallStatus: RECRUITING date: 2022-11-18 date: 2025-12-31 date: 2026-01-31 date: 2024-03-20 date: 2024-04-18 name: Ospedale Civico, Lugano class: OTHER_GOV briefSummary: Clinical implication of eventual blood biomarkers for stroke diagnosis and prognosis would be limited, mainly because clinical evaluation and scales (providing stroke severity) or neuroimaging (providing accurate size of the lesion) are more reliable predictors for clinical outcome prediction. In clinical practice, it would be more useful to find a biomarker, which can help to orientate the physician in conditions in which the clinical picture and imaging provide a limited support.
Transient Ischemic Attacks (TIAs) represent a classical example for which a biomarker would be of interest to confirm and distinguish a brain ischemic process from a stroke mimic. Diagnostic biomarkers of TIA have been investigated, but none of the potential candidates reached enough accuracy for TIA diagnosis. Our group has found that Extracellular Vesicles (EVs) could be useful as biomarkers for detecting brain ischemia in patients with TIA because the EV-surface antigen profile appears to be different in patients with transient symptoms, adjudicated to be very likely caused by brain ischemia, compared to patients whose symptoms were less likely to due to brain ischemia. Our study has raised interest in the scientific community recognizing the promising role of of blood-derived EVs analysis in expanding the possibilities to correctly diagnose and classify TIA and stroke events, discriminate them from TIA or stroke mimics, with important future implications in management and therapy of the patients with acute ischemic cerebrovascular syndrome. the validity of our approach needs to be tested in a larger, prospective, multicenter study. conditions: Stroke, TIA, Stroke-mimics, Stroke Biomarkers studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: Extracellular vescicles (EV) analysis measure: TIA differentiation from TIA mimics measure: TIA differentiation from Stroke measure: Stroke etiology sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Neurocenter of Southern Switzerland, Ospedale Civico status: RECRUITING city: Lugano state: Ticino zip: CH-6900 country: Switzerland name: Carlo Cereda, MD role: CONTACT phone: +41 91 811 6691 email: carlo.cereda@eoc.ch name: Carlo Cereda role: PRINCIPAL_INVESTIGATOR name: Giovanni Bianco role: SUB_INVESTIGATOR name: Lucio Barile role: SUB_INVESTIGATOR lat: 46.01008 lon: 8.96004 hasResults: False
nctId: NCT06319729 id: REC/22-23/0659 briefTitle: A Chinese Herbal Medicine for IBS-C acronym: CDD2105RCT1 overallStatus: NOT_YET_RECRUITING date: 2024-03-25 date: 2024-08-31 date: 2024-11-30 date: 2024-03-20 date: 2024-03-21 name: Hong Kong Baptist University class: OTHER briefSummary: This double-blind, placebo-controlled randomized pilot clinical trial will test the hypothesis that granules of CDD-2105, a Chinese herbal medicine formula, will have efficacy in alleviating constipation and abdominal pain in individuals with IBS-C. Participants (n=78) will be randomly assigned to the treatment or placebo group in a 1:1 ratio, followed by 4 weeks of intervention and 4 weeks of follow-up. conditions: Constipation-predominant Irritable Bowel Syndrome studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A double-blind, placebo-controlled randomized clinical trial primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: All the study drugs and placebo should be in the same package with the same drug appearance and blinded according to the randomized numbers of the subgroups. The specific blinding method is set as follows: the study drugs and placebo are uniformly packaged and numbered according to the corresponding randomized group results. One copy of the blinding letter in duplicate is sent with the test drug to the project leader of the test center for storage, and the other copy is kept by the pharmacy until the end of the trial. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 78 type: ESTIMATED name: CDD-2105 name: Placebo measure: Abdominal Pain Responder Rate measure: Complete Spontaneous Bowel Movement (CSBM) Responder Rate measure: Change in the weekly average self-assessed daily maximum abdominal pain scores (0-10) measure: Change in the number of days of abdominal pain per week measure: Change in the average weekly Complete Spontaneous Bowel Movement (CSBM) frequency measure: Change in the average weekly Spontaneous Bowel Movement (SBM) frequency measure: Change in the score of Irritable Bowel Syndrome-Severity of Symptoms (IBS-SSS) questionnaire measure: Change in the score of Patient Assessment of Constipation-Symptoms (PAC-SYM) measure: Change in the score of Patient Assessment of Constipation Quality of Life (PAC-QoL) questionnaire measure: Safety: number of adverse events measure: Safety: the level of liver function (ALT, AST, AKP, GGT, TBIL, DBIL) and renal function (blood urea nitrogen, creatinine) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False